US Pharma MarketingESMO first look: Zai Lab, GSK, Merck and others detail wins, setbacks
ESMO 2026 abstracts: Zai Lab’s ZL-1310 posts 80% ORR in first-line SCLC, GSK’s ris-rez hits 61% and Merck details its RCC flop. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
The last time the ESMO congress was in Madrid, a presentation on first-line data in bladder cancer drew a rapturous standing ovation. Contenders that might draw the same reception include hotly anticipated ...
Source: Endpoints News